NCT02031679View on ClinicalTrials.gov

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Chronic Idiopathic Urticaria
Interventions
DRUG

AZD1981

AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).

DRUG

Placebo

Sugar pill manufactured to mimic AZD1981 10 mg tablet

Trial Locations (1)

21224-6821

Johns Hopkins Asthma and Allergy Center, Baltimore

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Johns Hopkins University

OTHER